---
title: 786-0 CDX Model - TD2 Precision Oncology
description: 786-0 is a renal cell carcinoma cell line widely used for studying RCC and testing therapeutic interventions.
image: https://td2inc.com/hubfs/Assets/GraphsFigures/786-0-CDX-Model.png
---
×
[](https://td2inc.com/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
# 786-0 CDX Model
**Synonyms:** 786O
The 786-0 cell line is derived from a primary human renal cell carcinoma (RCC), representing the clear cell subtype. It is a valuable tool for studying the pathogenesis of RCC and evaluating therapeutic approaches. 786-0 exhibits key molecular features and genetic alterations observed in RCC patients, making it a representative model for preclinical investigations. Its in vitro and in vivo behavior closely reflects the characteristics of RCC, including patterns of growth, angiogenesis, and potential responses to targeted therapies. Researchers utilize 786-0 not only to deepen their understanding of RCC biology but also to develop and test novel treatment strategies, especially in the context of targeted and immunotherapies.
## Model Details
**Cancer Location:** Kidney
**Cancer Type:** Renal Cell Carcinoma
**Model Name:** 786-0
**Mouse Strain:** Nu/Nu
**Treatment Data Available:** Chemotherapy (Lenvantib, Axitinib, Bevacizumab)
## 786-O Growth curves: Response to Lenvatinib, Axitinib dosed, Bevacizumab
Growth of subcutaneous 786-O in Nu/Nu mice (n=10)
### Request Additional CDX Model Data
## CONTACT US
## Get Started.
Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.
[Get Started Now](https://td2inc.com/contact-us/?hsLang=en)
[](https://td2inc.com/?hsLang=en)
Office
13208 E. Shea Blvd,
Suite 100
Scottsdale, AZ 85259
Phone
(602) 358-8300
Connect with us
-
-
© 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)